EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pyridoxine supplementation ameliorates SGPL1 R222Q variant sphingosine phosphate lyase insufficiency syndrome in mice

Ranjha Khan, Maria L Allende, Ehtesham Khalid, Joanna Y Lee, Everett Stone, Max Rodnick-Smith, Audrey Izuhara, Vadym Buncha, Georgina Gyarmati, Janos Peti-Peterdi, Ranya Al-Khaledy, Jeffrey B Hodgin und 7 weitere

Journal of Clinical Investigation · 16.11.2026 · 136 (22)

DOI: 10.1172/jci206980 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 24.09.2026. Verfasst von Ranjha Khan und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, UCSF School of Medicine, San Francisco, California, USA. Hauptthemen laut MEDLINE: Aldehyde-Lyases, Pyridoxine, Nephrotic Syndrome, Dietary Supplements. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NICHD NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sphingosine-1-phosphate lyase insufficiency syndrome (SPLIS) is a rare condition causing nephrotic syndrome, neuropathy, and other manifestations. SPLIS is caused by mutations in SGPL1 , which encodes sphingosine-1-phosphate lyase (SPL), a pyridoxal 5′-phosphate–dependent (PLP-dependent) enzyme needed to degrade the bioactive sphingolipid sphingosine-1-phosphate (S1P). Supplementation with the PLP precursor pyridoxine benefits some individuals with PLP-dependent enzymopathies. We investigated whether pyridoxine has therapeutic activity in SPLIS. Neurological improvement, plasma S1P normalization, and increased SPL activity in patient-derived fibroblasts were observed after pyridoxine supplementation in a patient with R222Q-variant SPLIS. Additionally, PLP dose-dependently augmented recombinant R222Q-variant SPL activity. To further explore pyridoxine’s effects, gene editing was employed to create an R222Q-variant SPLIS mouse model. SPL R222Q mice fed pyridoxine-enriched chow lacked obvious phenotypes. However, SPL inactivation, S1P accumulation, proteinuria, and glomerulosclerosis developed in SPL R222Q but not WT mice fed chow with reduced pyridoxine. Ultrastructural analysis and super-resolution microscopy showed podocyte loss and foot process effacement. Transcriptional profiling revealed patterns of cytokine upregulation and extracellular matrix remodeling. Inhibiting S1P production or RhoA/ROCK signaling prevented nephrosis in SPL R222Q mice fed chow lacking pyridoxine. Our findings establish a SPLIS mouse model that recapitulates R222Q-variant SPLIS, demonstrates its responsiveness to pyridoxine, and implicates a S1P/RhoA/ROCK pathway in its pathophysiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aldehyde-LyasesPyridoxineNephrotic SyndromeDietary SupplementsMutation, MissenseAnimalsMiceHumansDisease Models, AnimalLysophospholipidsFemaleMaleFibroblasts

Stichwörter der Autor:innen

MetabolismMonogenic diseasesMouse modelsNephrologyTherapeutics

Substanzen

Aldehyde-LyasesPyridoxineSGPL1 protein, humanSgpl1 protein, mouseLysophospholipidssphingosine 1-phosphate lyase (aldolase)

Autor:innen und Institutionen

  • Department of Pediatrics, UCSF School of Medicine, San Francisco, California, USA.
  • Genetics and Biochemistry Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland, USA.
  • Ochsner Clinical School/University of Queensland (Australia) and Ochsner Health, New Orleans, Louisiana, USA.
  • Department of Molecular Biosciences, University of Texas, Austin, Texas, USA.
  • Department of Oncology, University of Texas Dell Medical School, LIVESTRONG Cancer Institutes, Austin, Texas, USA.
  • Department of Physiology and Neuroscience and Department of Medicine, Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, California, USA.

Förderung

  • NIDDK NIH HHS
  • NICHD NIH HHS
  • NCATS NIH HHS
  • NIH HHS
  • California Institute for Regenerative Medicine
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • NIH Office of the Director
  • Center for Clinical and Translational Research

Zitieren

APA

Khan, R., Allende, M. L., Khalid, E., Lee, J. Y., Stone, E., Rodnick-Smith, M., Izuhara, A., Buncha, V., Gyarmati, G., Peti-Peterdi, J., Al-Khaledy, R., Hodgin, J. B., Tassew, G., Oskouian, B., Chen, A., Chang, Y. T., Zhang, R., Proia, R. L., & Saba, J. D. (2026). Pyridoxine supplementation ameliorates SGPL1 R222Q variant sphingosine phosphate lyase insufficiency syndrome in mice. Journal of Clinical Investigation, 136(22). https://doi.org/10.1172/jci206980

Vancouver

Khan R, Allende ML, Khalid E, Lee JY, Stone E, Rodnick-Smith M, et al. Pyridoxine supplementation ameliorates SGPL1 R222Q variant sphingosine phosphate lyase insufficiency syndrome in mice. Journal of Clinical Investigation. 2026;136(22). doi:10.1172/jci206980

BibTeX
@article{Khan2026,
  author = {Khan, Ranjha and Allende, Maria L and Khalid, Ehtesham and Lee, Joanna Y and Stone, Everett and Rodnick-Smith, Max and Izuhara, Audrey and Buncha, Vadym and Gyarmati, Georgina and Peti-Peterdi, Janos and Al-Khaledy, Ranya and Hodgin, Jeffrey B and Tassew, Gizachew and Oskouian, Babak and Chen, Alina and Chang, Yu-Tang and Zhang, Rachel and Proia, Richard L and Saba, Julie D},
  title = {Pyridoxine supplementation ameliorates SGPL1 R222Q variant sphingosine phosphate lyase insufficiency syndrome in mice},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {22},
  doi = {10.1172/jci206980}
}
Kostenlos starten →